CD274 and non-small cell lung carcinoma: The multi‐centre, randomised, open‐label phase III clinical trial IMpower150 evaluated the efficacy of atezolizumab (a PD‐L1 inhibitor) combined with chemotherapy (carboplatin + paclitaxel) and bevacizumab (an anti‐VEGF antibody) in patients with advanced NSCLC.